Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Sosei Heptares and Neurocrine hope to be able to achieve the benefits of muscarinic agonists without the toxicity, in a single molecule. "Our selective muscarinic agonist approach is supported by ...

Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold company shares valued at $181,129. The transactions, executed on February 13, 2025 ...

Neurocrine Biosciences has a twelve month low of $110.95 and a twelve month high of $157.98. The firm’s 50-day moving average price is $138.28 and its 200 day moving average price is $130.92.

Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $11.7 billion market cap biopharmaceutical company, recently sold 700 shares of the company's common ...

SAN DIEGO—Kevin Charles Gorman, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), sold a total of 5,844 shares of the company's common stock on February 13, 2025, according to a recent SEC ...

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...